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1. Summary  
 
Background: Fusarium is a mold mainly known as plant and animal 
pathogen. Recently, there has been an increasing number of reports 
about fusarium infection in humans, especially as opportunistic 
infection in immunocompromised patients with a significant morbitiy 
and mortality rate. The aim of this study is to further elucidate the 
behavior of fusariosis in humans. 
 
Methods: We analyzed all reports of Fusarium infection in the 
English and German literature from 1958 to 2007. Data about the 
age, gender, underlying condition, symptoms, Fusarium species, 
treatment and outcome were analyzed. 
 
Results: 213 cases with either histologically or culture proven 
infection were included. 62.5% (n=133) were male. The median age 
of the patients was 39.9 years (range: 0.04-82 years). The overall 
mortality rate was 34.7% (n=74), with a direct correlation between the 
underlying condition, the immune status of the patient and the site of 
infection. No underlying condition was found in only 4.2% (n=9) of all 
cases. All of them survived and none of them had a disseminated 
disease. A disseminated infection was detected in 40% (n=86) of all 
analyzed cases with fusariosis. The second leading site of Fusarium 
infection was the skin 22.5% (n=48) and eye 15% (n=33). Fusarium 
solani was the most frequent species. 92.5% (n=197) of all patients 
received antifungal therapy. The most frequent used antifungal agent 
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was amphotericin B deoxycholate and its liposomal equivalent. Only 
6 patients received no treatment at all, neither surgery nor any sort of 
medication. 4 of them died.  
 
Conclusion: From the first case in 1958 an increasing number of 
cases were published each decade with a peak between 1990-1999. 
The outcome depends on the site of infection and the immune status 
of the patient. Disseminated Fusariosis in immunocompromised 
patients had a very poor outcome. Usually a recovery is achieved as 
soon as the immune status of the patient improves.
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2. Introduction 
 
The mold Fusarium is a common soil saprophyte, and it is worldwide 
distributed in plants, soil and water (49, 53, 57, 92). Fusarium species 
were also detected in the hospital water systems and outdoor air (94). 
Fusarium species are important plant pathogens. Fusarium infections 
in humans are rare and used to be mostly associated with superficial 
mycosis (53). However, locally invasive and systemic infections are 
observed with increasing frequency in immunocompromised patients 
and have recently emerged as opportunistic fungal infections among 
these patients (53, 94). With the widespread use of cytoreductive and 
immunosuppressive therapy in patients with hematological 
malignancies, Fusariosis has recently become an emerging disease 
in immunocompromised patients (8, 9, 24, 50, 87, 94).  
Fusarium species is a fungus of hyalohyphomycosis along with other 
fungi such as Penicillium species, or Aspergillus species. 
More than 50 species of Fusarium have been described but only a 
few of them have been recognized as pathogenic for humans (94). 
The most common is Fusarium solani (9, 94). Followed by Fusarium 
oxysporum (2, 3, 7, 15, 23, 37, 40, 44, 54, 58, 62, 68, 83, 85, 93, 102-
104, 109, 110, 113, 114, 116, 117, 121, 128, 131, 138, 140) and 
Fusarium moniliforme (28, 32, 43, 48, 63, 89, 98, 109, 136, 138, 142). 
Others found in the literature are Fusarium verticilliodes (38, 78, 105, 
119, 137), Fusarium proliferatum (16, 59, 108, 129), Fusarium 
dimerum (12, 20, 26, 68, 71), Fusarium chlamydosporum (66, 125), 
Fusarium roseum (99), Fusarium conglutinans (76), Fusarium 
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napiforme (81), Fusarium sacchari (50) and Fusarium polyphialidicum 
(51). The fungus Fusarium sp. possesses several virulence factors 
including the production mycotoxins. These mycotoxins can suppress 
humoral and cellular immunity, and cause tissue breakdown.  
Fusarium spp. also have the ability to adhere to prosthetic material 
(contact lenses, catheters) (92). 
The clinical manifestation of fusarosis correlates directly with the 
immune status of the patient and the portal of entry (94). An infection 
in healthy patients is rare and occurs usually only after direct 
inoculation or breakdown of the tissue barrier (79). It affects mostly 
skin and eyes (19, 53, 57). However, Fusariosis is one of the most 
common cause of fungal keratitis world-wide (19).  
In immunocompromised patients, especially those with prolonged 
neutropenia the Fusarium infection often results as an invasive or 
disseminated disease (49). The most frequent clinical manifestation 
of disseminated fusariosis in these patients is refractory fever despite 
antibacterial and antifungal therapy with typical cutaneous lesions 
and positive blood culture (49, 79, 87, 94).  
Due to this fact and the knowledge of the increasing number of 
immunosuppressed patient the aim of this study is to further elucidate 
the pattern of the Fusarium infection. We reviewed the English and 
German language literature for all cases of fusariosis, from the 
original case report in 1958 to 2007. In this review, we sought to 
understand the pattern of the infection, whether the infection is 
associated with specific host factors, the portal of entry, treatment 
and outcome.
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3. Methods 
 
We conducted a systematic literature search of the MEDLINE, to 
identify all reported cases with an infection due to Fusarium sp. After 
the initial search we scanned the references listed on each 
publication to gain additional cases. Only cases with either 
histologically or culture proven Fusarium infection were included.  
Data about the anatomical location of the infection, risk factors (e.g. 
immunosuppression, antibiotic treatment, steroids, and injury), age 
and gender of the patient, treatment and outcome were collected and 
analyzed.  
A disseminated infection was defined as an infection at two or more 
noncontiguous sites.  
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4. Results 
 
213 cases of fusariosis were included in our analysis. In 1958, the 
first case of Fusarium infection was mentioned in a patient after an 
eye injury due to a cowtail (83). The inflamed eye was treated with 
antibiotics and steroids without improvement. Pus in the anterior 
chamber and a perforated ulcer developed. A smear finally proved a 
Fusarium infection. The eye had to be enucleated in order to achieve 
a complete recovery from the infection. From this first case of 
Fusarium infection an increasing number of cases were published in 
the literature in each decade, reaching a peak between 1990-1999 
(figure 1). 
 
Demographic characteristics 
The median age of all patients was 38.95 years with a range from 
0.04-82 years. 72 patients (33.8%) were over the age of 50 years, 26 
patients (12.2%) under the age of 10 years. A total of 62.4% (n=133) 
of all Fusarium infections occurred in males, 35.2% (n= 75) in 
females. In 2% (n=5) of all cases the gender of the patient was not 
mentioned at all.  
The overall mortality rate was 34.7% (74 of 213 Patients did not 
survive the infection), 49.7% (n=106) achieved a complete recovery. 
In the remaining 15.6% (n=33) there was either a stable disease or 
the patient was lost to follow-up.  
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The most common underlying condition and major risk factor to 
become infected from a Fusarium sp. was any antibiotic treatment 
(63.9%), followed by hematologic malignancies (44.1%). 
Predisposing job or hobbies, such as farming or gardening were 
found in 6.1% of the cases. However, 77.4% (n=164) of all patients 
had more than just one risk factor. No underlying condition was found 
in only 9 cases (4.2%). All 9 cases had a localized infection and 
survived (table 1). 
 
Change of Fusarium infections during study period   
In 1950-1959 trauma was the most common underlying condition. 
After 1960 the leading underlying condition in each decade was any 
use of antibiotics. Hematologic malignancies were not known as 
underlying condition until 1970. After 1980 it became the second 
most underlying condition with a peak in 1990-1999 (figure 1).  
However, over all decades the hematologic malignancies with 
consecutive chemotherapy and neutropenia, which requires the 
broad use of antibiotics, are the most important risk factors of 
Fusarium infections.  
Besides the medical progress with its associated ICU treatments, 
foreign devices in the body, such as catheters and grafts are 
frequently associated with Fusarium infections.  
 
 
 10 
Sites of infection 
Fusarium infection can be superficial, locally invasive or 
disseminated. The site of infection depends mainly on the underlying 
condition and correlates directly with the immune status of the patient 
and the site of entry (table 1). 
A disseminated infection was diagnosed in 74.4% (n=64) of all cases 
associated with a hematologic malignancy. Chemotherapy and 
neutropenia are also important risk factors to develop a disseminated 
infection (65.1% of all cases, n=56 in both cases).  
In 69.6% (n=23) of all eye infections there was a prior antibiotic 
treatment. The second underlying risk factor for eye infections was 
the use of local steroids (51.5%, n=17), followed by foreign devices in 
the eye such as contact lenses (42.4%, n=14) and trauma (36.3%, 
n=12).  
Regarding the skin infection, the most common risk factor was also 
the use of antibiotics (47.9%, n=23), followed by hematologic 
malignancies (39.6%, n=19), chemotherapy (35.4%, n=17) and 
neutropenia (29.1%, n=14).  
Positive blood cultures was obviously often associated with foreign 
devices, such as catheters and grafts (81.9%, n=9).  
In most cases of nail infections no underlying condition could be 
found (71.5%). 
Bone infections were often associated with diabetes mellitus (50%),  
All patients with Fusarium endocarditis had an intravascular catheter. 
The two cases with peritonitis were both associated with peritoneal 
dialysis.  
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Clinical manifestation 
The clinical manifestation depended on the site of infection.  
The most frequent clinical manifestation in patients with disseminated 
fusariosis was refractory fever. Further typical cutaneous lesions 
were mentioned in 44% of all disseminated cases. Skin lesions 
presented themselves as erythematous painful cutaneous or 
subcutaneous papular nodules.  
Pulmonary infiltrations were found in 23% of the cases with 
disseminated fusariosis. An eye infection usually presents itself by 
decreasing vision and painful watery injected eyes, later with corneal 
ulcer. In nail infection a yellow or white discoloration periungular was 
seen.  
 
Microbiological findings 
The most common species was F. solani in 34.3%, followed by F. 
oxysporum in 17.8%, F. moniliforme 5.6%. Only sporadic infections 
with F. verticilloides, F. proliferatum, F. dimerum F. roseum, F. 
chlamydosporum, F. conglutinans, F. polyphialdicum, F. napiforme, 
F. sachari were reported (table 1). In 26.4% (n=63) the exact species 
was not documented. F. solani seems to be the most virulent species. 
34.9% (n=25) of all disseminated infections are caused by F. solani 
and 30.1% (n=22) of all patients with F. solani infection died. F. 
oxysporum was in 17.4% (n=15) associated with a disseminated 
disease, F. moniliforme and F. verticilliodes in 5.8% (n=5). F. 
proliferatum and F. dimerum were only found in 3 patents with 
disseminated disease.
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Figure 1:  Number of patients mentioned in the literature with 
Fusarium infection per decade.
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Table 1: Demographic and clinical characteristics  
 
Characteristic  No. of patients No. of patients who died 
Total 213  74/213 (34.7%) 
Age 
• mean 
• range 
 
38.95 
0.04-82 
 
Sex 
• male 
• female 
• unknown 
 
133 (62.4%) 
 75 (35.2%) 
   5  (2.4%) 
 
   
Underlying condition 
• Medication 
- steroids 
- antibiotics 
• Tumor 
- solid organ 
- hematologic 
• Transplantation 
- kidney 
- liver 
- heart/liver 
- lung 
- bone marrow 
• Trauma/burns 
• Foreign body 
- catheter 
- contact lens 
- graft 
- nasogastric tube 
- dialysis 
• no  
 
 
  31 (14.6%) 
136 (63.9%) 
 
  15 (7%) 
  94 (44.1%) 
 
   3 (1.4%) 
   1 (0.5%) 
   1 (0.5%) 
   3 (1.4%) 
 27 (12.7%) 
 34 (16%) 
  
 25 (11.7%) 
 15 (7%) 
   3 (1.4%) 
   2 (0.9%) 
   3 (1.4%) 
   9 (4.2%) 
 
 
   9 (29%) 
 56 (41.2%) 
 
   7 (46.7%) 
 46 (48.9%) 
 
   2 (66.7%) 
   0 
   0 
   2 (66.7%) 
 20 (74.0%) 
   3 (8.8%) 
 
 11 (44%) 
   0 
   3 (100%) 
   0 
   0 
   0 
Site of infection 
• disseminated 
• skin 
• eye 
• ORL 
• blood 
• nail 
• bone 
• joint 
• lung 
• endocarditis 
• peritoneum 
 
 86 (40.4%) 
 48 (22.5%) 
 33 (15.5%) 
 10 (4.7%) 
 11 (5.2%) 
   8 (3.8%) 
   6 (2.8%) 
   3 (1.4%) 
   3 (1.4%) 
   3 (1.4%) 
   2  (0.9%) 
 
 50 (58.1%) 
 12 (25%) 
   0 (0%) 
   4 (40%) 
   1 (9.1%) 
   0 
   0 
   1 (33.3%) 
   1 (33.3%) 
   3 (100%) 
   0 (0%) 
Species 
• F. solani 
• Species unknown 
• F. oxysporum 
• F. moniliforme 
• F. verticilliodes 
• F. proliferatum 
• F. dimerum 
• F. roseum 
• F. chlamydosporum 
• F. conglutinans 
• F. polyphialidicum 
• F. napiforme 
 
 73 (34.3%) 
 63 (29.6%) 
 38 (17.8%) 
 12 (5.6%) 
   7 (3.3%) 
   7 (3.3%) 
   5 (2.4%) 
   2 (0.9%) 
   2 (0.9%) 
   1 (0.5%) 
   1 (0.5%) 
   1 (0.5%) 
   1 (0.5%) 
 
 22 (30.1%) 
 22 (34.9%) 
 14 (36.8%) 
   6 (50%) 
   3 (42.9%) 
   2 (28.6%) 
   3 (60%) 
   0 (0%) 
   1 (50%) 
   0 
   0 
   0 
   0 
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Treatment 
The treatment depended on the site of infection. 197 (92.5%) of the 
reviewed 213 cases were treated with any antifungal therapy. Most of 
the patients received a combination of different antifungal 
pharmaceuticals. Only 6 patients (3 with disseminated, 1 with burns 
and 2 with skin infection) received no treatment at all, 4 of them died, 
among them the 2 cases with disseminated infections and the one 
with burns. In 3 of these cases the diagnosis of Fusarium infection 
was made post mortem.  
Surgery alone was used in 7 patients with superficial infection. All of 
them survived.  
The most widely used antifungal therapy was amphotericin B 
deoxycholate (62.5%,n=133) with its first use in 1964. The second 
most used was liposomal amphotericin B (17.5%, n=37), first 
administered in 1991. Followed by flucytosin (n=30), fluconazole 
(11.3%, n=24), voriconazole (12.2%, n=26), itraconazole (9.4%, 
n=20), ketokonazole (8.5%, n=18) and rifampicin (7.0%, n=15). 
Besides the antifungal therapy and surgery the use of Granulocyte 
transfusions and G-CSF transfusion was used.  
Between 1958-1959 none of the above mentioned antifungal therapy 
was known. Surgery was the treatment of choice. Later on, between 
1960-1969 the first antifungal therapy came in place. For a long time 
amphotericin B deoxycholate was the only known antifungal 
pharmaceutical, until 1979 when flucytosin came in place, followed by 
ketokonazole (1986). The first use of G-CSF was mentioned in 1990. 
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In 1991 the first use of liposomal amphotericin B was reported, 1992 
the first use of fluconazole, 1994 itraconazole and 2003 voriconazole.  
Many patients (27.2%, n=58) received a combination of antifungal 
agents. Rifampicin was never used as a single drug, but always in 
combination with an antifungal agent, most often with amphotericin B. 
In 56 of the 58 cases with a combination antifungal therapy, 
amphotericin B was one component of the combination. In the later 
decades voriconazole was widely used in a combination therapy. The 
most frequently used combination was amphotericin B/flucytosin 
(9.4%, n=20), followed by amphotericin B/voriconazole (3.8%, n=8), 
amphotericin B/rifampicin (3.3%, n=7) and amphotericin 
B/ketoconazole (1.9%, n=4). Other combinations used where 
amphotericin B/fluconazole in 3 cases, amphotericin B/itraconazole in 
2 cases and ketoconazole/rifampicin in 1 case.  
 
Triple combinations were used in 12 cases:  
• amphotericin B/flucytosin/rifampicin (n=2)  
• rifampicin/ketoconazole/amphotericin B (n=2) 
• amphotericin B/flucytosin/ketoconacole (n=2) 
• amphotericin B/voriconazole/fluconazole (n=2) 
• amphotericin B/fluconazole/itraconazole (n=1) 
• amphotericin B/voriconazole/itraconazole (n=1) 
• amphotericin B/flucytosin/itraconazole (n=1) 
• amphotericin B/fluconazole/rifampicin (n=1) 
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The use of voriconazole in combination with another antifungal drug 
seems to be a successful treatment with a recovery rate of 90%. On 
the other hand rifampicin in combination with an antifungal agent 
seems to be a poor choice: 69.2% of the patients didn’t survive the 
infection. 53.5% of the patient who received a combination therapy 
survived.  
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Table 2: Treatment administered to 213 patients with fusariosis 
 
Treatment No. of patients No. of patients who 
died 
Amphotericin B 
- deoxycholate 
- lipid/liposomal 
 
133 (17.5%)    
  37 (17.5%) 
 
 56 (42.1%) 
 12 (32.4%) 
Flucytosin    30 (14.1%)  17 (20.3%) 
Fluconazole   24 (11.3%)  11 (45.8%) 
Voriconazole   26 (12.2%)    1 (3.8%) 
Itraconazole   20 (9.4%)    6 (30%) 
Ketoconazole   18 (8.5%)    5 (27.8%) 
Rifampicin   13 (6.1%)     9 (69.2%) 
Surgery   75 (35.2%)  13 (17.3%) 
G-Transfusion   12 (5.7%)    6 (50%) 
G-CSF   25 (11.8%)  12 (42.9%) 
No therapy    6 (2.9%)    4 (33.3%) 
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Outcome 
The overall mortality was 34.7% (n=74). A complete recovery was 
achieved in 49.7%. 15.5% of the patients were lost to follow-up was. 
The mortality rate was strongly associated with the underlying 
condition and the site of infection. A disseminated infection is 
obviously associated with a worse outcome. 58.1% of all patients with 
disseminated infections died, whereas only in 36.0% a complete 
recovery was achieved. A disseminated fusariosis was only seen in 
immonocompromised patients. 
All 3 patients with a Fusarium endocarditis didn’t survive. 25% of the 
patient with a skin Fusarium infection died. An eye infection leaded 
never to death.  
An underlying hematologic malignancy was the most important risk 
factor for death. 48.9% (n=46) of all patients with hematologic 
malignancies didn’t survive the infection.  
All patients with no underlying condition survived the infection.  
Regarding the mortality rate per decade there is a notable increase in 
the mortality rate each decade, reaching a peak in the 1990-1999 
with 51.9% patients with fusariosis dying (figure 2). This trend was 
attributed to the widespread and, immunosuppressive therapy and 
increasing use of antibiotics. Finally a decrease of the death rate was 
recognizable in the time of 2000-2007 with a mortality rate of 16.4% 
(12 of 69 patients). In most cases it was seen that as soon as the 
patients achieves a recovery of its own body defense, he will recover 
from the infection.  
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Figure 2: number of patients (light) and death rate in % (dark) 
compared to decade 
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5. Discussion 
 
 
Fusariosis is an emerging disease, especially in 
immonocompromised patients. Fusarium spp. causes a broad 
spectrum of infections in humans, including superficial, locally 
invasive, and disseminated infections (94). To our knowledge, this is 
the first study including all published Fusarium infections. The first 
reported case of a Fusarium infection was in 1958 (83). Unlike other 
known filamentous fungal pathogens, Fusarium affects mostly 
immunocompromised hosts. Our study showed that, in contrast to 
other mold infections, such as zygomycetes (112), diabetes or solid 
tumors don’t seem to be important risk factors to get infected with 
Fusarium ssp.. Only a few cases, namely 10 were found in patients 
with solid tumor. Only 4 cases were observed in patients with 
diabetes mellitus as a risk factor. All of them had a localized infection, 
either a skin infection or an infection in the otorhinolaryngological site. 
Each one achieved full recovery. No underlying condition was found 
in 9 cases at all.  
The most important risk factor for severe fusariosis is prolonged 
neutropenia in patients suffering from a hematologic malignancy, 
including especially hematopoietic stem cell transplantions.  
Fusarium infection is in the vast majority of the cases caused by a 
breakdown of the human defense. Either by trauma with affects the 
natural skin defense, or in immunocompromised hosts. Fusariosis is 
rare in a healthy person and occurs usually only after direct 
inoculation or tissue breakdown (as caused by trauma, severe burns 
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or foreign body). No disseminated infection was found in healthy 
people. However, infections include keratitis, onychomycosis and 
occasionally peritonitis and cellulitis. Treatment is usually successful 
and requires surgery, removal of a possible foreign body as well as 
antifungal therapy. 
In disseminated fusariosis refractory fever and cuatenous lesions are 
the most important symptoms. Type of skin lesions includes ecthyma-
like, target, and multiple subcutaneous nodules. Skin lesions lead to 
diagnosis in > 50% of patients and precede fungemia by 
approximately 5 days. In contrast to aspergillosis, fusariosis 
frequently shows positive blood cultures. This is because Fusarium 
spp. sporulate, which facilitates bloodborne disseminated growth 
(13).  
The culture methods typically have a low sensitivity for identifying the 
Fusarium species. Species identification may be difficult and may 
require the use of molecular techniques. PCR methods are  available 
but the identification is complex and requires a highly skilled 
laboratory staff (27). The use of mass spectrometry to identify the 
Fusarium ssp. has recently gained popularity (27). Matrix-assisted 
laser desorption ionization-time of light (MALDI-TOF) is a tool that 
has been used to characterize fungi (27, 31, 132). But so far there is 
no standard protocol or validated database to use the MALDI-TOF in 
a routine lab (27). The most common species found in our study was 
F. solani, followed by F. oxysporum, F. moniliforme, F. verticilloides, 
F. proliferatum and F. dimerum. In our study, F. solani seemed to be 
the most virulent species with the highest mortality rate.  
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Optimal treatment has not been established, yet. Anecdotal 
successes have been reported with various agents (high-dose 
amphotericin B, lipid-based amphotericin B formulations, 
itraconazole, voriconazole) and with cytokine-stimulated granulocyte 
transfusions. A study of Astor et al. (13) analyzed the susceptibility of 
the different Fusarium ssp. to antifungals in vitro. The result showed 
that terbinafine was most effective, followed by voriconzole and 
amphotericin B. In our study terbinafine was not used in the treatment 
of fusariosis. However, Combinationtherapies containing voriconazole 
showed a favorable outcome. Further studies should be conducted 
addressing the terbinafine in combination with voriconazole in 
treatment of an infection due to Fusarium spp.  
 
Given the poor prognosis associated with disseminated fusariosis in 
immunocompromised patients, prevention is the cornerstone of 
management (94). The high risk patients have to be in rooms with 
HEPA filters. Further, contact with reservoirs of Fusarium spp. such 
as food or tap water should be avoided.  
In conclusion, infections by Fusarium spp. can be superficial or 
limited to single organs in non immunocompromised host. Such 
infections are rare and tend to respond well to therapy. By contrast, 
disseminated fusariosis occurs in the immunocompromised host, 
especially in hemato-oncological patients with severe and prolonged 
neutropenia. These patients die frequently in this setting, and 
successful outcome is determined largely by the degree and 
persistence of immunosuppression. Fusariosis may be clinically 
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suspected on the basis of the clinical presentation and laboratory 
findings. A prompt therapy should be started.  
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